A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies

Relapsed/Refractory Hematological Malignancies Clinical Trial

Official title:
A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3473 Tablets

Status Recruiting

Clinical Trial Summary

This is a study to evaluate the maximum tolerated dose (MTD), occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3473 tablets in Chinese adult patients with Relapsed or refractory hematological malignancies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hematologic Neoplasms
Neoplasms
Relapsed/Refractory Hematological Malignancies

Clinical Trial Details

NCT number	NCT04412577
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact	Peng Liu, Doctor
Phone	021-60267405
Email	Liu.peng@zs-hospital.sh.cn
Status	Recruiting
Phase	Phase 1
Start date	October 12, 2020
Completion date	June 2022

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05528887` - Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies	Phase 1